By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Investment firm Rodman & Renshaw has upgraded Sequenom's stock to "Market Perform" from "Market Underperform" following yesterday's publication by the San Diego-based firm of results on its non-invasive fetal trisomy 21 test.
Registering provides access to this and other free content.
Already have an account?Login Now.
Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.
Bill Gates tells the Telegraph that bioterrorism is a serious risk.
The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.
CBS News reports that the White House Science Fair is to continue under President Donald Trump.